Public criticism fails to derail approval of Acelrx’s opioid painkiller, but not without a lengthy apologia from Scott Gottlieb.
Medicare is to review ways to encourage use of non-addictive pain relievers, but Heron Therapeutics will miss out on extension of a special payment provision.
Companies like Nanjing Legend and Cellular Biomedicine Group continue to attract major financial endorsement from Western big pharma, but the threat of scandal is…
Private price negotiation is a hallmark of the US health care system – banning rebates does not make that any less true.
Government document seeks comment on scheme for physician-administered drugs.
Drug price inflation has slowed to crawl, but political pressure can only keep a lid on costs for so long.
Questions about hallucination and deaths continue to swirl around Acadia's Nuplazid.
Biopharma companies have benefited from public funding for their early research, so do they have the right to charge high prices for these projects?
The high doses of recently studied gene therapies threaten manufacturing problems that few have fully considered.